Monopar Therapeutics
MNPR
#8837
Rank
โ‚น7.51 B
Marketcap
โ‚น1,424
Share price
7.31%
Change (1 day)
824.27%
Change (1 year)

P/E ratio for Monopar Therapeutics (MNPR)

P/E ratio as of November 2024 (TTM): -21.9

According to Monopar Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -21.9221. At the end of 2022 the company had a P/E ratio of -14.3.

P/E ratio history for Monopar Therapeutics from 2019 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-14.3-34.17%
2021-21.7-58.89%
2020-52.8-74.35%
2019-206

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-4.71-78.53%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.